



ASX Announcement

22 July 2026

Cambium Bio Raises A\$1.0 Million via Placement to Existing Strategic Shareholder

Sydney, Australia; 22 July 2026: Cambium Bio Limited (ASX:CMB) ("Cambium Bio", "Cambium" or "Company"), a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair, is pleased to announce that it has received a firm commitment to raise A\$1,008,000 through the placement of 2,100,000 new fully-paid ordinary shares at A\$0.48 per share ("**Placement**").

Key Highlights

- Firm commitment to raise **A\$1,008,000** via the issue of 2,100,000 new fully-paid ordinary shares at A\$0.48 per share.
- Issue price of A\$0.48 represents a **17.1% premium** to the Company's closing share price of A\$0.41 on 21 July 2026.
- Placement made to Mr Chun Yi Wu (Brandon Wu), an existing shareholder who holds significant interests in the regenerative medicine sector. His relevant interest in Cambium Bio increases from approximately 12.25% to approximately 18.5%.
- New shares to be issued under the Company's existing 10% placement capacity under ASX Listing Rule 7.1A. No shareholder approval is required.
- Proceeds form part of a broader, ongoing capital raise strategy to finance the pivotal Phase 3 trial of Elate Ocular® in moderate to severe dry eye disease.
- Settlement and issue of the new shares are expected to occur within five business days.

Placement Details

The Placement comprises the issue of 2,100,000 new fully-paid ordinary shares at A\$0.48 per share, raising A\$1,008,000. The issue price of A\$0.48 represents a 17.1% premium to the Company's closing share price of A\$0.41 on 21 July 2026, demonstrating confidence in the value of Cambium Bio and its Phase 3 Elate Ocular® program.

The new shares will be issued under the Company's existing 10% placement capacity under ASX Listing Rule 7.1A, as approved by shareholders at the Annual General Meeting held on 16 October 2025. Accordingly, the Placement does not require shareholder approval. The new shares will rank equally with the Company's existing fully-paid

For personal use only

ordinary shares on issue. The Company did not engage any external adviser in connection with the Placement, and transaction costs are nominal. The Company will provide a cleansing notice under section 708A(5) of the Corporations Act 2001 (Cth) in respect of the new shares. Settlement and issue of the new shares, and their quotation on ASX, are expected to occur within five business days of the date of this announcement.

Continued Support from a Strategic Shareholder

The Placement was subscribed by Mr Chun Yi Wu (Brandon Wu), an existing shareholder of Cambium Bio who holds significant interests in the regenerative medicine sector. Following completion of the Placement, Mr Wu's relevant interest in Cambium Bio will increase from approximately 12.25% to approximately 18.5%. Mr Wu is not a related party of the Company. His continued support reflects ongoing confidence from a strategic shareholder aligned with the Company's focus on regenerative medicine.

Capital Raise Strategy and Phase 3 Program

The Placement forms part of a broader, ongoing capital raise strategy to finance the Company's pivotal Phase 3 trial of Elate Ocular® for the treatment of moderate to severe dry eye disease. The pivotal Phase 3 program comprises a single 475-patient trial, which the FDA has confirmed is sufficient to support the submission of a Biologics License Application (BLA) for Elate Ocular®.

CEO Commentary

Karolis Rosickas, Chief Executive Officer of Cambium Bio, commented:

"Cambium Bio is excited to see continued support from our existing strategic shareholders through this placement. More broadly, we are seeing growing interest from strategic partners and investors in our Elate Ocular® dry eye disease program, where a significant unmet need remains and there is clear demand for novel therapeutics that offer a superior efficacy and safety profile. This investment, priced at a premium to market, reflects confidence in the value of Cambium Bio and enables us to continue advancing our pivotal Phase 3 program."

- ENDS -

Forward-Looking Statements

This announcement may contain forward-looking statements, including statements regarding the Company's capital raising, clinical development plans, the timing and outcome of its pivotal Phase 3 program, and its intended regulatory submissions. Forward-looking statements are based on the Company's current expectations and assumptions and involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Regulatory and clinical outcomes are not certain, and target dates are qualified targets and not commitments. The Company does not undertake any obligation to update forward-looking statements except as required by law.

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised for release by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio